𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Significance of CD44 Expression in Gastrointestinal Stromal Tumors in Relation to Disease Progression and Survival

✍ Scribed by Kai-Hsi Hsu; Hung-Wen Tsai; Yan-Shen Shan; Pin-Wen Lin

Publisher
Springer
Year
2007
Tongue
English
Weight
277 KB
Volume
31
Category
Article
ISSN
0364-2313

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Expression of Bcl-2 in gastrointestinal
Expression of Bcl-2 in gastrointestinal stromal tumors : Correlation with progression-free survival in 81 patients treated with imatinib mesylate
✍ Dejka M. Steinert; Mauricio Oyarzo; Xuemei Wang; Haesun Choi; Peter F. Thall; L. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy. Before imatinib, Bcl‐2 expression in GIST was associated with a worse prognosis or added no additional prognostic value. To the authors' knowledge

CD44 expression in benign, premalignant,
CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression
✍ Saegusa, Makoto; Machida, Daisuke; Hashimura, Miki; Okayasu, Isao πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 484 KB πŸ‘ 2 views

To clarify the possible role of CD44 expression in ovarian tumour development and progression, an immunohistochemical investigation was undertaken of a series of 115 carcinomas, 32 tumours with low malignant potential (LMP), and 53 cystadenomas. A combination of the reverse transcription-polymerase

Protein expression of cancer testis anti
Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors
✍ Daniel Perez; Fabian Hauswirth; Dirk JΓ€ger; Urs Metzger; Eleftherios Pierre Sama πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 304 KB

## Abstract Cancer testis antigens (CTAs) have been identified in various tumors as immunological tumor targets. In gastrointestinal stromal tumor (GIST), the prediction of malignant potential remains difficult but is crucial in the era of adjuvant imatinib treatment. Here, we analyzed the impact o

Resection of residual disease in patient
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
✍ Sebastian Bauer; JΓΆrg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabell πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 723 KB

## Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Long‐term survival of patients with metastatic disease has only been observed in patients with completely resected disease. Recently, the tyrosine kinase inhibitor imatinib has b